journal
MENU ▼
Read by QxMD icon Read
search

Pharmacopsychiatry

journal
https://www.readbyqxmd.com/read/28521367/driving-problems-in-the-elderly-and-cognitively-impaired
#1
Robert Haussmann, Maria Buthut, Markus Donix
Driving ability in the elderly and cognitively impaired is of growing demographic relevance. Driving represents a complex task for which multiple central resources are needed. In mild cognitive impairment and dementia, we need to closely monitor driving ability, as it gets irrecoverably lost in the course of the disease. In normal aging, people are often able to self-regulate driving behavior with respect to their medical conditions. Some studies demonstrated that older drivers perform well compared with younger drivers...
May 18, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28511206/antipsychotic-treatment-of-22q11-2-deletion-syndrome-related-psychoses
#2
Elias Angelopoulos, Christos Theleritis, Marina Economou, Korina Georgatou, Charalambos C Papageorgiou, Eleftheria Tsaltas
In the recent study by Verhoeven and Egger, 2015 and the recent letter to the editor by Boot et al. 2015 an emphasis is given to the best possible pharmacological treatment of 22q11-2 Deletion-Syndrome related psychoses. We would like to present the case of a 23-year old Cypriot patient with 22q11.2 deletion syndrome who fulfilled criteria for treatment resistant schizophrenia (TRS). He was sequentially treated with aripiprazole, risperidone, olanzapine, haloperidol and a combination treatment with olanzapine and haloperidol...
May 16, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28505669/add-on-antidepressants-in-the-naturalistic-treatment-of-schizophrenia-spectrum-disorder-when-who-and-how
#3
Rebecca Schennach, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G Schmidt, Wolfgang Gaebel, Joachim Klosterkötter, Isabella Heuser, Wolfgang Maier, Matthias R Lemke, Eckart Rüther, Stefan Klingberg, Markus Gastpar, Ilja Spellmann, Richard Musil, Hans-Jürgen Möller, Michael Riedel
The aim of this study was to evaluate antidepressant add-on treatment within the acute treatment of schizophrenia spectrum disorder patients. Antidepressant add-on was evaluated in 365 patients within a naturalistic multicenter study. Patients with/without antidepressant add-on were compared regarding clinical and treatment-related variables, response and remission, and remission of depressive and negative symptoms. The efficacy of antidepressant add-on treatment was furthermore analyzed applying marginal structure models...
May 15, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28482360/new-onset-of-suicidal-impulses-following-abrupt-cessation-of-valproate
#4
Johannes Ladwig, Dorothea Andreae, Renate Grohmann, Sermin Toto, Stefan Kropp, Stefan Bleich
No abstract text is available yet for this article.
May 8, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28482359/author%C3%A2-s-reply-to-the-letter-to-the-editor-by-fountoulakis
#5
Shahin Akhondzadeh, Alireza Ghajar
No abstract text is available yet for this article.
May 8, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28444658/comparing-the-immune-genomic-effects-of-vilazodone-and-paroxetine-in-late-life-depression-a-pilot-study
#6
Harris Eyre, Prabha Siddarth, Natalie Cyr, Hongyu Yang, Steve Cole, Malcolm Forbes, Helen Lavretsky
Vilazodone is a novel antidepressant agent that combines selective serotonin (5-HT) reuptake inhibitor (SSRI) activity and 5-HT(1A) receptor partial agonist activity. A pilot study was conducted to compare vilazodone (novel compound) and paroxetine (gold standard) on antidepressant effects, tolerability, and inflammation and immune modulation. A 12-week, double-blind, randomized clinical trial was conducted with 56 nondemented older adults diagnosed with major depressive disorder (MDD). Between-group differences in mood, tolerability, and safety, as well as genomic markers of inflammation and immune modulation, were examined...
April 25, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28351080/is-really-crocus-sativus-as-effective-as-citalopram-in-the-treatment-of-depression
#7
Konstantinos N Fountoulakis
No abstract text is available yet for this article.
March 28, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28346959/mirtazapine-induces-nightmares-in-depressed-patients
#8
Jens-Armin Buschkamp, Corinna Frohn, Georg Juckel
No abstract text is available yet for this article.
March 27, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28293921/effects-of-intramuscular-midazolam-and-lorazepam-on-acute-agitation-in-non-elderly-subjects-a-systematic-review
#9
Sabrina Just Kousgaard, Rasmus W Licht, René Ernst Nielsen
Benzodiazepines are commonly used for the treatment of acute agitation in a psychiatric setting.We searched MEDLINE, EMBASE, PsycINFO, and the Cochrane Central Register of Controlled Trials (CENTRAL) for relevant publications. Randomized trials evaluating intramuscular (IM) midazolam or lorazepam given as monotherapy or as add-on treatment, with more than 10 patients aged 18-65 years, conducted in a psychiatric setting, and published between January 1, 1980, and February 3, 2016, were included. 16 studies from a search result of 5 516 studies were included...
March 14, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28278537/paliperidone-long-acting-plasma-level-monitoring-and-a-new-method-of-evaluation-of-clinical-stability
#10
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Chiara Rovera, Alessio Fiorentini, Carlo Alfredo Altamura
The second generation long-acting antipsychotics can be a pharmacologic strategy, both in the early phase of illness and in the case of low compliance. The aim of the study was to evaluate the clinical efficacy and tolerability of one monthly injection of paliperidone palmitate (PP1M), paliperidone plasma levels (PLs), and the clinical outcome. 21 outpatients, affected by Schizophrenia or Schizoaffective Disorder, were recruited. PP1M started with 150 mg on day 1 and 100 mg on day 8. Following patients were given a dosage ranging from 50 mg to 150 mg every 28 days...
March 9, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28445899/evidence-based-guidelines-for-the-pharmacologic-management-of-methamphetamine-dependence-relapse-prevention-chronic-methamphetamine-related-and-comorbid-psychiatric-disorders-in-post-acute-settings
#11
Roland Härtel-Petri, Anne Krampe-Scheidler, Wolf-Dietrich Braunwarth, Ursula Havemann-Reinecke, Peter Jeschke, Winfried Looser, Stephan Mühlig, Ingo Schäfer, Norbert Scherbaum, Lydia Bothe, Corinna Schaefer, Willem Hamdorf
The increasing abuse of the street drug crystal meth (methamphetamine) in many countries worldwide has resulted in a growing demand to treat patients who have acquired a methamphetamine-related disorder. The results of a systematic literature search which led to the consensus-based recommendations by the Working Group of the German Agency for Quality in Medicine (Ärztliches Zentrum für Qualität in der Medizin - ÄZQ) are presented. Pharmacological treatments were reviewed in 58 out of the 103 publications included...
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28445898/dramatic-changes-over-time-of-methamphetamine-intake-in-a-german-hiv-positive-sample-of-men-who-have-sex-with-men-msm
#12
Henrike Dirks, Stefan Esser, Norbert Brockmeyer, Udo Bonnet, Fabrizio Schifano, Norbert Scherbaum
No abstract text is available yet for this article.
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28444659/new-psychoactive-substances-nps-a-challenge-for-the-addiction-treatment-services
#13
Norbert Scherbaum, F Schifano, Udo Bonnet
Over the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europe. Apart from some herbal compounds, NPS mainly include synthetic cannabinoids and a range of new synthetic stimulants (e. g., cathinones). Synthetic NPS are often developed whilst modifying the basic chemical (e. g., phenethylamine or tryptamine) structure. Although the pharmacology and toxicology of most NPS are hardly known, they are being offered, especially online, as "bath salts," as "incense mixtures," or under other misleading labels...
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28437807/when-the-evidence-is-not-enough-commentary-on-h%C3%A3-rtel-petri-et-al
#14
R McKetin, S Allsop
No abstract text is available yet for this article.
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28420010/consumption-of-methamphetamine-during-pregnancy-transgenerational-substance-misuse
#15
Stefan Gutwinski, Andreas Heinz
No abstract text is available yet for this article.
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28351079/editorial-to-methamphetamine-crystal-meth-and-new-psychoactive-substances
#16
Ulrich S Zimmermann
No abstract text is available yet for this article.
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28297728/evidence-based-guidelines-for-the-pharmacological-management-of-acute-methamphetamine-related-disorders-and-toxicity
#17
Norbert Wodarz, Anne Krampe-Scheidler, Michael Christ, Heribert Fleischmann, Winfried Looser, Katharina Schoett, Frank Vilsmeier, Lydia Bothe, Corinna Schaefer, Euphrosyne Gouzoulis-Mayfrank
No abstract text is available yet for this article.
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28178739/methamphetamine-consumption-during-pregnancy-effects-on-child-health
#18
Jürgen Dinger, Patricia Hinner, Jörg Reichert, Mario Rüdiger
Methamphetamine abuse during pregnancy represents an emerging health care problem. The consequences are not only of relevance to the pregnant women, but also their unborn child. It is associated with an increased risk of preeclampsia and hypertension, fetal demise, preterm delivery, and intrauterine growth restriction. The deleterious effects of prenatal methamphetamine exposure on the developing fetal brain may lead to long-term neuro-developmental and behavioral problems.Given the current evidence, abuse of methamphetamine during pregnancy must be of utmost concern to health care professionals and to policy-makers...
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28208190/real-world-effectiveness-of-antipsychotics-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia-with-predominantly-negative-symptoms
#19
MULTICENTER STUDY
Diego Novick, William Montgomery, Tamas Treuer, Maria Victoria Moneta, Josep Maria Haro
This study assessed the comparative effectiveness of antipsychotics in the treatment of patients with schizophrenia presenting with prominent negative symptoms and no-to-mild positive symptoms. Data were taken from a 3-year prospective, international, observational study (n=17 384). This post-hoc study focused on 3 712 patients who started antipsychotic monotherapy and had moderate-to-severe negative symptoms and no-to-mild positive symptoms (Clinical Global Impression-Severity Scale [GGI-SCH]). Patients were classified into 3 treatment cohorts: olanzapine, other atypicals and typicals...
March 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/27978584/ppar-%C3%AE-agonists-for-the-treatment-of-major-depression-a-review
#20
REVIEW
R Colle, D de Larminat, S Rotenberg, F Hozer, P Hardy, C Verstuyft, B Fève, E Corruble
Introduction: Selective agonists of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ) are used for the treatment of type 2 diabetes. We reviewed their efficacy and safety for the treatment of major depression and the association of their potential antidepressant effects with changes in biomarkers of metabolism and inflammation. Methods: From 8 studies, 4 open-label trials, and 4 randomized controlled trials (RCT) (3 vs. placebo and 1 vs. metformin), 448 patients with major depression were included, of which 209 patients received PPAR-γ agonists (pioglitazone or rosiglitazone) for 6-12 weeks, either alone or in add-on therapy to conventional treatments...
March 2017: Pharmacopsychiatry
journal
journal
28729
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"